Cyclophosphamide for scleroderma lung disease: A systematic review and meta-analysis

Rheumatology International

Volumn 32, Issue 8, 2012, Pages 2431-2444

  Poormoghim, Hadi ^a   Lakeh, Maziar Moradi ^a   Mohammadipour, Mastoureh ^a   Sodagari, Faezeh ^a   Toofaninjed, Neda ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cyclophosphamide; Interstitial lung disease; Meta analysis; Systematic review; Systemic sclerosis

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FAMOTIDINE; GRANISETRON; HISTAMINE H2 RECEPTOR ANTAGONIST; ILOPROST; LISINOPRIL; MESNA; METHYLPREDNISOLONE; METOCLOPRAMIDE; OMEPRAZOLE; PREDNISOLONE; PROTON PUMP INHIBITOR; VASODILATOR AGENT;

DETERIORATION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FORCED VITAL CAPACITY; HEMATURIA; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LOW DRUG DOSE; LUNG ALVEOLITIS; LUNG DIFFUSION CAPACITY; LUNG LAVAGE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TREATMENT OUTCOME; ULCER; VOMITING;

CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG DISEASES, INTERSTITIAL; PULMONARY DIFFUSING CAPACITY; SCLERODERMA, SYSTEMIC; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84866247180     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-1967-y     Document Type: Review

References (40)

1. Minai OA, Dweik RA, Arroliga AC (1998) Manifestations of scleroderma pulmonary disease. Clin Chest Med 19:19
2. Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr (1994) Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 37(9):1290-1296
3. Hesselstrand R, Scheja A, Akesson A (1998) Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57:5
4. Steen V (2003) Scleroderma renal crisis. Rheum Dis Clin North Am 29:19
5. Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Boutin le TH, Cacoub P, Frances C, Wechsler B, Grenier P, Piette JC (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54(1):8
6. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132(12):947-954
7. Steen V, Medsger TA (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43(11): 8
8. Mayes M, Lacey JJ, Beebe-Dimmer J, Gillespie B, Cooper B, Laing T et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48(8):10
9. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20(5):838-844
10. Akesson A, Scheja A, Lundin A, Wollheim FA (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37(5):729-735
11. Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, Konig G et al (1996) Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 154(2 Pt 1):400-406
12. Varai G, Earle L, Jimenez SA, Steiner RM, Varga J (1998) A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 25(7):1325-1329
13. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29(2):298-304
14. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML et al (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29(4):731-736
15. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655-2666
16. Latsi PI, Wells AU (2003) Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 15(6):748-755
17. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18(6):455-461
18. Nannini C, West PC, Erwin JP, Matteson JE (2008) Effect of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arth Res Therapy 10:R124. doi:10.1186/ar2534
19. ATS idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement (2000) Am J Respir Crit Care Med 161: 646-664
20. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:12
21. Schnabel A, Reuter M, Gross WL (1998) Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 41(7):1215-1220
22. Moher D, Cook D, Eastwood S, Olkin I, Rennie D, Stroup D (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354(9193):5
23. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS et al (2006) A multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962-3970
24. Nadashkevich O, Davis P, Fritzler M, Kovalenko W (2006) A randomized unblended trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25:205-212. doi:10.1007/s10067-005-1157-y
25. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P (2002) Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29(11):2371-2378
26. Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC et al (2003) Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48(8):2256-2261
27. Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L et al (2007) Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol 26(2):168-172
28. Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G, Kalliolias G, Liossis SN et al (2007) Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 27(4):357-361
29. Ostojic P, Damjanow N (2006) Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy. Clin Rheumtol 25:819-821
30. Simeon-Anzar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva-o Callaghan A, Solans-Laque R, Palliza E (2008) Intravenous cyclophosphamide puls therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. Open Respir Med J 2:39-45
31. Airo P (2007) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated to systemic sclerosis: results with an 18 month long protocol including a maintenance phase. Cli Exp Rheumatol 25:293-296
32. Valentine G (2006) Low dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 35:35-38
33. Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:8
34. Wells AU, Lorimer S, Majumdar S, Harrison NK, Corrin B, Black CM et al (1995) Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. Eur Respir J 8(2):266-271
35. LeRoy E (1989) Sentinel signs and symptoms of systemic sclerosis. Curr Opin Rheumatol 1:6
36. Owens G, Fino G, Herbert D, Steen V, Medsger T, Pennock B Jr et al (1983) Pulmonary function in progressive systemic sclerosis: comparison of CREST syndrome variant with diffuse scleroderma. Chest 84:5
37. Southcott AM, Jones KP, Li D, Majumdar S, Cambrey AD, Pantelidis P et al (1995) Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med 151(5):1604-1612
38. Corrin B, Butcher D, McAnulty BJ, Dubois RM, Black CM, Laurent GJ et al (1994) Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 24(2):145-150
39. Cohen J (1992) A power primer. Psychol Bull 112: 155-159. [http://psycnet.apa.org/index.cfm?fa=search.displayRecord&uid= 1992-37683-001]
40. Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L (2007) Interstitial lung disease associated with systemic sclerosis. What is the evidence for efficacy of cyclophosphamide? Ann N Y Acad Sci 1110:271-284